ArticleTranslational cancer research2020
Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- The Significance of the Microenvironment in T/Nk-Cell Neoplasms.International journal of molecular sciences · 2025Review
- Clinical Impact of Microbiome Characteristics in Treatment-Naïve Extranodal NK/T-Cell Lymphoma Patients.Cancer research and treatment · 2025Article
- Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma.Annals of hematology · 2024Article
- B-Cell Activation Biomarkers in Salivary Glands Are Related to Lymphomagenesis in Primary Sjögren's Disease: A Pilot Monocentric Exploratory Study.International journal of molecular sciences · 2024Article
- Review
- EBV dUTPase: A Novel Modulator of Inflammation and the Tumor Microenvironment in EBV-Associated Malignancies.Cancers · 2023Review
- Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.Life (Basel, Switzerland) · 2021Review
- Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtranodal natural killer/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma (NHL), characterized as mature T- and natural killer (NK)-cell lymphoma, which is more common in East Asia and Latin America than in other parts of the world. The overproduction of proinflammatory cytokines such as interleukin-6 (IL-6) plays an essential role in the development of lymphoma.
methodsWe measured serum IL-6 and IL-6 related cytokines of 65 newly diagnosed ENKTL patients to assess biomarkers for prognosis of ENKTL.
resultsPatients with high IL-6 (>15.920 mg/L) at diagnosis had more adverse clinical features. Patients with low IL-6 (≤15.920 mg/L) at diagnosis had better progression-free survival (PFS; P=0.002), overall survival (OS; P<0.001), and higher complete remission rates (P=0.001). IL-6 correlated with lactate dehydrogenase (LDH), ferritin, C-reactive protein (CRP), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α). Multivariate analysis revealed Ann Arbor stage [P=0.001, risk ratio (RR) =6.011 (2.102-17.191)] and IL-6 [P=0.012, RR =2.367 (1.206-4.643)] to be independent prognostic factors for PFS. Multifactor analysis of OS revealed Ann Arbor stage [P=0.015, RR =3.600 (1.278-10.141)], IL-6 [(P=0.001), RR =3.565 (1.720-7.390)], and chemotherapy that not containing L-asparaginase [(P=0.009, RR =2.717 (1.252-5.780)] to be independent prognostic factors for shorter OS.
conclusionsThese results suggest serum IL-6 at diagnosis is predictive of prognosis for ENKTL, and IL-6 increase is activity during the pathogenesis of ENKTL and offers new insight into potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.